Piers David Nash | |
|---|---|
 Piers Nash | |
| Born | Exeter, England |
| Nationality | UK, Canada, US |
| Alma mater | University of Alberta University of Guelph Booth School of Business |
| Known for | Cellular signal transduction |
| Scientific career | |
| Fields | Biochemistry, cell biology |
| Institutions | University of Chicago |
| Doctoral advisor | Grant McFadden |
Piers David Nash is an entrepreneur, cancer biology professor, data evangelist, writer and technology futurist. He is the founder of Sympatic, and the son of academic Roger Nash.
Born in Exeter, England, and grew up in Sudbury, Ontario, Canada. In high school he competed in the Canada-Wide Science Fair in five successive years (1983–87), winning awards [1] on each occasion and becoming one of the most highly awarded science fair participants in the history of the fair. In recognition of this he was selected to represent Canada as one of two youth delegates to the 1985 Nobel Prize lectures and ceremony in Stockholm, Sweden as part of the Stockholm International Youth Science Seminar [2] and was awarded the International Youth Year Ontario Gold Medal. He received a BSc with honours in biochemistry from the University of Guelph, and the Chemical Institute of Canada prize for the top of class and President's Scholarship. [3] He received a PhD in 1999 from the University of Alberta working in the laboratory of Dr. Grant McFadden investigating poxviral immunomodulatory proteins. His doctoral thesis focused on the enzymology and biological properties of the Myxoma virus encoded serine proteinase inhibitor (serpin), SERP-1. [4] He completed postdoctoral research with Anthony Pawson at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and the University of Toronto from June 1999 to December 2003. [5] In 2014, Nash received an MBA with a concentration in finance awarded with high honors from the University of Chicago Booth School of Business. [6]
Nash is the founder and CEO of Sympatic Inc [7] which is developing Cloud SaaS to power ethical data sharing for applications such as Artificial Intelligence. Nash has authored three patents on advanced multi-party rule-based secure cloud run-time environments that allow rule-based multi-party access or code access to data (link to patents). Sympatic holds trademarks for VirtualVault® and Ethical Data Sharing® based on Nash's work. Nash is Founder & General Manager of Nash Strategy & Innovation. [8] He advises Fortune 500 technology companies and startups in the genomics, healthcare, data science and data storage fields. He serves on the Advisory Boards of technology and innovation companies. Nash was Managing Director at Health2047, [9] the innovation enterprise of the American Medical Association from 2017-2018. From 2014 to 2017, Nash was Director of the Center for Data-Intensive Science at the University of Chicago that was building and managing the National Cancer Institute Genomic Data Commons with Robert Lee Grossman. He was founding strategy manager and Director of business and research development for the University of Chicago's Center for Data Intensive Science which developed the National Cancer Institute Genomic Data Commons. He was a professor in the Ben May Department for Cancer Research and a Scientist of the Comprehensive Cancer Center at the University of Chicago from 2004–2012 and a fellow of the Institute for Genomics and Systems Biology [10] from 2006–2012. As a scientist, he investigates protein–protein interactions involved in signal transduction, and the molecular mechanisms by which cells respond to external cues. His work at the University of Chicago focused on understanding the SH2 domain at a systems level and investigating the role of ubiquitination in controlling endocytosis and modulating signal transduction. Earlier work focused on the emergent properties of complex systems such as ultrasensitivity (all-or-none switches) at critical junctures in the cell cycle.[ citation needed ]
ResearchGate reports 54 peer-reviewed published works in a wide range of fields, including signal transduction, cell biology, molecular evolution, cell cycle, cognition and memory, meteorology, and pedagogy. [11]
| Authority control databases: Academics |
|---|
The SRC Homology 3 Domain is a small protein domain of about 60 amino acid residues. Initially, SH3 was described as a conserved sequence in the viral adaptor protein v-Crk. This domain is also present in the molecules of phospholipase and several cytoplasmic tyrosine kinases such as Abl and Src. It has also been identified in several other protein families such as: PI3 Kinase, Ras GTPase-activating protein, CDC24 and cdc25. SH3 domains are found in proteins of signaling pathways regulating the cytoskeleton, the Ras protein, and the Src kinase and many others. The SH3 proteins interact with adaptor proteins and tyrosine kinases. Interacting with tyrosine kinases, SH3 proteins usually bind far away from the active site. Approximately 300 SH3 domains are found in proteins encoded in the human genome. In addition to that, the SH3 domain was responsible for controlling protein-protein interactions in the signal transduction pathways and regulating the interactions of proteins involved in the cytoplasmic signaling.
Signal transducing adaptor proteins (STAPs) are proteins that are accessory to main proteins in a signal transduction pathway. Adaptor proteins contain a variety of protein-binding modules that link protein-binding partners together and facilitate the creation of larger signaling complexes. These proteins tend to lack any intrinsic enzymatic activity themselves, instead mediating specific protein–protein interactions that drive the formation of protein complexes. Examples of adaptor proteins include MYD88, Grb2 and SHC1.
Anthony James Pawson was a British-born Canadian scientist.
The Max Planck Institute of Biochemistry is a research institute of the Max Planck Society located in Martinsried, a suburb of Munich. The institute was founded in 1973 by the merger of three formerly independent institutes: the Max Planck Institute of Biochemistry, the Max Planck Institute of Protein and Leather Research, and the Max Planck Institute of Cell Chemistry.
The SH2domain is a structurally conserved protein domain contained within the Src oncoprotein and in many other intracellular signal-transducing proteins. SH2 domains bind to phosphorylated tyrosine residues on other proteins, modifying the function or activity of the SH2-containing protein. The SH2 domain may be considered the prototypical modular protein-protein interaction domain, allowing the transmission of signals controlling a variety of cellular functions. SH2 domains are especially common in adaptor proteins that aid in the signal transduction of receptor tyrosine kinase pathways.
The Lunenfeld-Tanenbaum Research Institute is a medical research institute in Toronto, Ontario and part of the Sinai Health System. It was originally established in 1985 as the Samuel Lunenfeld Research Institute, the research arm of Mount Sinai Hospital, by an endowment from the Lunenfeld and Kunin families. It was renamed to the current name on June 24, 2013, after a $35 million donation from Larry and Judy Tanenbaum.
Myxoma virus is a poxvirus in the genus Leporipoxvirus. The two broad geographic types of myxoma virus are Californian and South American. Californian myxoma virus is found on the West Coast of the United States, the Baja Peninsula of Mexico, and the southwest coast of Canada. South American or Brazilian myxoma virus is found in South and Central America. South American myxoma virus circulates in the jungle rabbit or tapeti, whereas Californian myxoma virus circulates in the brush rabbit. In their native hosts, the viruses cause the formation of benign cutaneous fibromas rather than systemic disease.
NetPath is a manually curated resource of human signal transduction pathways. It is a joint effort between Pandey Lab at the Johns Hopkins University and the Institute of Bioinformatics (IOB), Bangalore, India, and is also worked on by other parties.
Maspin is a protein that in humans is encoded by the SERPINB5 gene. This protein belongs to the serpin superfamily. SERPINB5 was originally reported to function as a tumor suppressor gene in epithelial cells, suppressing the ability of cancer cells to invade and metastasize to other tissues. Furthermore, and consistent with an important biological function, Maspin knockout mice were reported to be non-viable, dying in early embryogenesis. However, a subsequent study using viral transduction as a method of gene transfer was not able to reproduce the original findings and found no role for maspin in tumour biology. Furthermore, the latter study demonstrated that maspin knockout mice are viable and display no obvious phenotype. These data are consistent with the observation that maspin is not expressed in early embryogenesis. The precise molecular function of maspin is thus currently unknown.
SHC-transforming protein 1 is a protein that in humans is encoded by the SHC1 gene. SHC has been found to be important in the regulation of apoptosis and drug resistance in mammalian cells.
SH2 domain–containing protein 1A is a protein that in humans is encoded by the SH2D1A gene. It is often called SLAM-associated protein, where "SLAM" refers to signaling lymphocytic activation molecules. It is a SH2 domain–containing molecule that plays a role in SLAM signaling. A putative function is as an adaptor for Fyn and competitor of phosphatases, leading to modulation of SLAM family function. SAP has been implicated in autoimmunity, and a mutation of it is associated with X-linked lymphoproliferative disease. At least 32 disease-causing mutations in this gene have been discovered.
Expenditures by Canadian universities on scientific research and development accounted for about 40% of all spending on scientific research and development in Canada in 2006.
David Julian Harry Downward FRS FMedSci is Associate Research Director at the Francis Crick Institute and Senior Group Leader at the Institute of Cancer Research. He was formerly head of the Signal transduction Laboratory at the London Research Institute. He is a member of the Editorial Board for Cell.
Warren Jackson Pledger is a molecular cell biologist who is the Associate Director for Basic Sciences, Tampa General Hospital Cancer Institute and Professor, Department of Molecular Medicine, Morsani College of Medicine, USF Health in Tampa, Florida. He had been a Professor, Department of Surgery, University of Utah School of Medicine and a member of the Cell Response and Regulation Program, Huntsman Cancer Institute. He was the Associate Center Director for Basic Science at the Moffitt Cancer Center and Research Institute. He has held academic appointments and tenure at the University of North Carolina School of Medicine, Vanderbilt University School of Medicine and the University of South Florida College of Medicine.
György Kéri was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
Kohzoh Imai is a Japanese physician and oncologist specializing in molecular diagnosis and novel medical treatment of cancer. He is well known for the discovery of a melanoma-related antigen by producing a monoclonal antibody. In addition, he produced monoclonal antibodies against CEA or ICAM-1 and found out they are usable in the diagnosis and the pathological analysis.
Anthony Rex Hunter is a British-American biologist who is a professor of biology at the Salk Institute for Biological Studies and the University of California San Diego. His research publications list his name as Tony Hunter.
Brenda Jean Andrews is a Canadian academic, researcher and biologist specializing in systems biology and molecular genetics.
Narayanaswamy Srinivasan was an Indian molecular biophysicist and a professor and the head of Proteins: Structure, Function and Evolutionary Group at the Molecular Biophysics Unit of the Indian Institute of Science. He is known for his researches in the fields of computational genomics and protein structure analysis. An elected fellow of the Indian Academy of Sciences and the National Academy of Sciences, India, he is a J. C. Bose National fellow of the Department of Biotechnology and a recipient of the National Bioscience Award for Career Development of the Department of Science and Technology. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2007, for his contributions to biological sciences.
Nevan J. Krogan is a Canadian molecular and systems biologist. He is a professor and the Director of the Quantitative Biosciences Institute (QBI) at the University of California San Francisco (UCSF), as well as a senior investigator at the J. David Gladstone Institutes.
